Excluding this study reduced heterogeneity (I2 = 42%), and reanalysis using a fixed-effects model indicated that patients receiving AT III had a higher risk of thrombosis events (RR = 1.53, 95% CI: 1.41–1.68, p < 0.001), as shown in Figure 7. The gene discussed is SERPINC1; the disease is deep vein thrombosis.